Research programme: RDP 58 analogues - Sanofi/Synt:em
Alternative Names: Research programme: RDP58 analogues - Sanofi/Synt:emLatest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation; Synt:em
- Class Small molecules
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 04 May 2006 No development reported - Preclinical for Inflammation in Europe (unspecified route)
- 30 Mar 2004 SangStat's operations have been absorbed into Genzyme Corporation's Cambridge site
- 18 Sep 2003 SangStat has been acquired by Genzyme Corporation